Pegfilgrastim Biosimilars Market Outlook Shows Government Initiatives Providing Aid In R&D

Pegfilgrastim Biosimilars Market Report 2020-30: Covid 19 Growth And Change

Pegfilgrastim Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change

The Business Research Company’s Pegfilgrastim Biosimilars Market Report – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, November 26, 2020 /EINPresswire.com/ — Avail up to 50% off on ALL research reports at: https://www.thebusinessresearchcompany.com/global-market-reports. Offer applies until Dec 31st.

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, in July 2018 to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative and in 2018 it improved its commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription and use of biosimilar medicines. These government initiatives for the development of biosimilars aid in increased production and awareness, which in turn supports the growth of the pegfilgrastim biosimilars market.

The global pegfilgrastim biosimilar market is expected to decline from $0.53 billion in 2019 to $0.45 billion in 2020 at a compound annual growth rate (CAGR) of -15.22%. The decline in this biosimilars pegfilgrastim market size is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $1.16 billion in 2023 at a CAGR of 36.75%.

The global pegfilgrastim biosimilars market report is segmented by application into chemotherapy treatment, transplantation, others, and by distribution channel into hospital pharmacies, retail pharmacies, mail-order pharmacies.

Here Is A List Of Similar Reports By The Business Research Company:

Filgrastim Biosimilars Global Market Report 2020-30: COVID 19 Growth and Change
(https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilars-global-market-report-2020-30-covid-19-growth-and-change)

Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
(https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market)

Trastuzumab Biosimilars Market Global Report 2020-30: COVID 19 Growth and Change
(https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilars-market-global-report-2020-30-covid-19-growth-and-change)

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire